Table 1

Patient demographics (n=26)

Age	Median (range)	57.6 (30.1–82.8)
Gender	Male	17
	Female	9
American Joint Committee on Cancer stage	III	4
	M1A	0
	M1B	3
	M1C	11
	M1D	7
Primary site	Cutaneous	17
	Acral	4
	Subungual	1
	Unknown primary	4
Driver mutation	BRAF	10
	NRAS	5
	Other*	2
	No driver identified	6
	Not tested	3
Tumor mutation burden	High	11
	Low	11
	Unknown	4
First course of ipi/nivo	Median # doses (range)	4 (1–4)
	# of patients receiving maintenance anti-PD1	16
Reinduction course of ipi/nivo	Median # of doses (range)	3 (1–4)
Months between courses	Median (range)	22.2 (6–49.1)

*One patient had KRAS G12V; the other had two NF1 alterations, X421_splice and Q392* and SF3B1 G740E.
ipi/nivo, ipilimumab/nivolumab.